Directorate Change

Premaitha Health plc

("Premaitha" or the "Company")

Directorate Change

Manchester, UK - 6 July 2016 - Premaitha Health PLC (AIM: NIPT) announces that Dr Charles Roberts, Non-executive Director, is stepping down from the Board with immediate effect. Dr Roberts was a partner at Loxbridge Research LLP which, as announced on 13 April 2016, is no longer a shareholder in the Company.

David Evans, Chairman, commented: "I would like to thank Charlie for his contribution to Premaitha. He was one of the early backers of the business and we wish him well in his future endeavours."

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For more information, please contact:

About Premaitha

Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.

Premaitha's lead test - the IONA® test - was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA® test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow-up diagnostic procedures which are costly, resource intensive and carry a risk of miscarriage.

Non-invasive prenatal screening is an emerging, multi-billion dollar global market and Premaitha's complete CE marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening system in-house. 

Premaitha is based in Manchester Science Park, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.